̽»¨ºÏ¼¯

Initiating buprenorphine for opioid use disorder (OUD) in outpatient settings is more difficult for patients using fentanyl. There are research and published literature supporting this trend.

Explore how long-acting injectable buprenorphine (LAIB) provides a barrier-free way to initiate OUD treatment for patients using fentanyl.

From the rescheduling of cannabis and the surging prevalence of nicotine pouches like Zyn, to the structural setbacks face-to-face with the alcohol industry, our field is moving at a breakneck pace.

One last commentary as EIC.

Social Media Use Trajectories and Substance Use Experimentation

Explore the limits of empathy in healthcare. Learn how peer mentor O’Nesha Cochran’s lived experience challenges stigma and helps providers honor patient dignity.

Inclusion criteria

Endtroducing

Too much of a good thing

Medications for opioid use disorder (MOUD), and overdose education and naloxone distribution (OEND), are among the most supported evidence-based practices (EBPs) in addiction medicine. Yet the real-world deployment of those EBPs at scale in diverse communities remains limited. Research shows that stigma toward these EBPs, toward people who use drugs or people receiving MOUD, plays a significant role in limiting the deployment and use of these EBPs in communities impacted by the opioid crisis.